Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01863069 | Avonex®: Safety, Blood Levels and Effects | PHASE1 | COMPLETED | 77 | — | — | Jan 1, 2001 | Oct 1, 2001 | May 27, 2013 | 1 | United Kingdom |
Serum concentrations of human interferon-beta
Serum concentrations of neopterin and beta2-microglobulin
Adverse events throughout the study
Routine physical examination, ECG, safety tests of blood/urine, CXR, oximetry, full pulmonary function tests, spirometry, Dyspnea scale
Cellular MxA protein as an exploratory analysis
| Name | Type | Description |
|---|---|---|
| Interferon beta 1a | DRUG | - |
| (IM) AVONEX® | DRUG | - |
Inclusion Criteria: * Must be between the ages of 18 and 45 years, inclusive. * Must have a body mass index (BMI) of 19 to 28 kilograms/height (m)2, inclusive, and have a minimum body weight of 50 kilograms (at screening and baseline). * Must give written informed consent. Exclusion Criteria: * H...